^
Association details:
| Biomarker: | BCR-ABL1 I432T |
|---|---|
| Cancer: | Chronic Myeloid Leukemia |
| Drug: | Bosulif (bosutinib) (Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome–positive chronic myeloid leukemia patients with resistance or intolerance to imatinib
Excerpt:
Among the 115 patients with known mutations at baseline, the most common were M351T (n = 7), F359V (n = 7), F317L (n = 4), L248V (n = 4), G250E (n = 3), M244V (n = 3), and T315I (n = 3). Similar rates of CHR or MCyR were observed between patients with and without mutations. Responses were observed broadly across Bcr-Abl mutants, except for T315I (Figure 3 and supplemental Table 3).
DOI:
https://dx.doi.org/10.1182%2Fblood-2011-05-355594
Trial ID:
